Some Lucentis patients have had detached retinas and serious infections inside the eye. If the eye becomes red, sensitive to light, or painful, or if there is a change in vision, patients should call ...
The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...
ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...
Switzerland's Novartis and Roche were fined 444 million euros ($522 million) by France, after its competition authority said on Wednesday they used abusive practices to push costly eye injection ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. An FDA advisory panel recommended Thursday that Genentech ...
Treating people in the early stages of diabetes-related eye disease may help slow the progression of the condition, but a new study also suggests that it can’t help prevent vision loss in the future.
Building on this success, the Alberta government says it is launching a new permanent program, the Alberta Retinal Treatment Program, effective Oct. 1. The new program is expected to expand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback